MEDIUM conviction · 145 dossiers

Theme cluster led by RXO peer name. Stated win-probability p=0.62. A genuine freight-cycle upturn after a multi-year trucking recession: brokerage, LTL and truckload volumes and spot rates are re-accelerating, lifting asset-light and…

Defense-electronics turnaround re-rating inside an accelerating modernization tape: Q3 FY26 (2026-05-06) printed record bookings $348M (+73.7% YoY), 1.48 book-to-bill, record ~$1.6B backlog and +46% EBITDA, with FCF guided positive. But…

Identity-security re-rating entering a second, sell-side-led leg: a post-print upgrade wave (KeyBanc street-high $175 on 07-10, Scotiabank upgrade to $165 on 07-06) is still building six weeks after the 05-29 beat-and-raise, lifting the…

Margin-recovery re-rate has carried the ACA pure-play leader to new highs, clearing the $30.38 prior 52-wk high on the +11% July 1 break with managed-care breadth (CNC/MOH/AGL) accelerating. But at $30.54 it trades ~28% above the $23.8…

Freight-cycle recovery intact; sell-side has fully caught up into a $20–35 battleground bears $20 (Goldman 07-16, Susquehanna 07-14), bulls $30–35 (BMO $35 initiation 07-14, Stifel/Truist/Citi $30). Narrative matured from mispriced to…

NAND-controller toll-booth on the steepest flash shortage in ~15 years: TrendForce H1 2026 contract +>100% cumulative, H2 still rising with no capacity adds. Q1 record +105% YoY, sell-side chasing to $400/$450. Fundamental leg…

Q2 blowout (rev $19.575B vs $16.8B est, 6/25) broke the seasonal guide-down bear case and the sell-side is chasing higher (MS $374, UBS $352). The channel re-rating is now confirmed by fundamentals, but the catalyst is spent and the next…

AI-native manufacturing marketplace re-rating on a profitability inflection Q1 marketplace revenue +40% YoY, FY guide raised, Siemens embed plus ~$50M stock buy. Wedbush 7/16 Outperform $126 reopens Street upside above spot after June's…

Freight-cycle upturn is the accelerating narrative: LTL volume and contract pricing re-accelerating after a multi-year trucking recession, with SAIA May tonnage +8.4% confirming the cluster. XPO layers operating-ratio self-help (Q1 LTL OR…

July recovery read failed: SOXX -18.6% MTD (worst month since 2008) with Apple's $30B deal, a record $7.1B ETF inflow and TSMC's record Q2 all sold into. Backlog intact, tape distributing theme now MATURING, and the four hyperscaler capex…

Tokenization/crypto-exchange leg still intact Robinhood Chain driving real on-chain ETH volume and Goldman raising to $137 (7/16) but CLARITY Act odds fell to 35%, Trump Accounts reframed as a 6.5M-vs-70M shortfall, and ARK is selling. The…

Optical-AI picks-and-shovels leader: the post-print -8.45% sell-the-news fully reversed and LITE led the tape to fresh records into June. Theme still ACCELERATING with cluster confirmation, but the 2026-06-09 cohort crater (Marvell -12%,…

Titanium/superalloy aero-defense supplier digesting a June breakout rather than reversing it: $186.17 (7/17) holds above the reclaimed $183.30 ATH shelf, RSI cooled to ~66, and consensus PT $200.33 now sits above spot after three…

AI-memory capex cycle re-accelerating: Lam's March-qtr beat (rev $5.84B, +24% YoY) plus Micron's blockbuster late-June print confirm the WFE order read-through, and 2026 WFE was lifted to ~$140B. But it's up ~119% YTD at mid-50x trailing…

Liquid-cooling/datacenter-power bottleneck story intact and the theme is still accelerating, but the stock's own revision cycle flattened RBC trimmed its target to $418 on 07-16 and Baird initiated below street-high at $370. The…

Bitcoin-miner-to-HPC re-rate confirmed: Anthropic's 20-year ~$19B AI-infrastructure lease (2026-07-06) is the named-tenant catalyst the tape was missing; theme ACCELERATING with a wall of raises (MS $72, 2026-07-08), but a ~$3.5B financing…

BASX data-center cooling re-rating (2026-05-07 Q1: rev +54%, FY guide doubled to 40-45%, backlog +107% to $2.13B) is still accelerating, but the repricing gap already fired, insiders sold into it, and the 2026-07-30 Q2 print is the next…

Busted-platform turnaround re-accelerated: broke the $6.79 ceiling to a new 52-wk high $8.44 off the June $5.09 base, now retesting the breakout shelf near $6.88. Jazz TCE deal validated the discovery engine and Benchmark's 2026-07-07 $11…

Post-scandal behavioral-health turnaround re-rating: UBS lifted its target to $39 on 2026-07-09 (from $31, above the $30.20 52-wk high) atop a clean Q1 and raised FY26 guide, with ~29% short interest as squeeze fuel into the ~2026-07-28 Q2…

Special-situation breakup narrative accelerating: Reuters (2026-07-17) reports ACI exploring a ~$1.5B sale of its Biller unit, which would surface sum-of-the-parts value and re-rate the faster-growing Payments Software segment. Q1 beat +…

China WFE-localization plus a memory-capex rebound is re-accelerating ACMR's order book (new orders +65% YoY at the 2026-05-07 Q1 print); the stock broke to an all-time high $109.87 on 2026-06-18 on Roth's raised $125 target. Narrative…

clonoSEQ MRD pure-play inflecting to self-funding growth (MRD rev +53% YoY, profitability turning); June 15 Immune Medicine separation adds a value-unlock leg. But the tape just broke to fresh 52-wk highs (~$22.92) above the $20–22…

Q3 FY26 killed the credit-stress bear case (GMV +35%, first GAAP operating profit, clean delinquency), and a July sell-side cluster six PT raises/initiations to $96–$117 in ten days is accelerating the re-rate off the mid-June 200-day…

Mitapivat SCD label-expansion re-rate: positive RISE UP Phase 3 (Jun 15) + FDA Priority Review acceptance (Jul 7, ~+15%) + same-day PT cluster to $46. The binary payoff is the ~Nov 1 2026 PDUFA; the acceptance pop is already digested and…

AI-agent-security narrative re-firing after a ~22% correction: AKAM ripped +10.7% to $126.57 (2026-07-08) on its unified agentic Bot & Agent Control framework, a LayerX deal and Oppenheimer's $180 call. A legacy-CDN-to-AI-security/compute…

AI rack-connectivity narrative now analyst-confirmed: BofA $450 / Stifel $460 / UBS $400 targets (late June) vacated the stale ~$253 average, arriving as the theme accelerates and semis rebound off the June Broadcom flush. Beta 3.96, and…

Airline sector broke a six-year downtrend as the Hormuz fuel spike rolls over into sticky post-Spirit airfares; ALK is a fuel-relief earnings-inflection recovery layered on the Hawaiian transformation but the move already ran two months…

Orexin (OX2R) re-rate has moved from discovery to consensus: 2026-07-13 long-term extension data confirmed durable wakefulness and Needham lifted PT to $62, but JPMorgan reinstated Neutral at $60 as spot presses the $56–62 target band.…

Best-in-class oral TYK2 narrative accelerating after Phase 3 psoriasis wins (PASI 100 ~40% at Week 24); the Q3 2026 LUMUS Phase 2b lupus topline is the binary that either re-rates the platform into a multi-billion indication or caps it as…

Physical-AI pure-play narrative accelerating: Rosenblatt named AMBA a top H2-2026 pick (2026-07-01, PT $120) and the stock ripped ~28-32% off the June flush, reclaiming $72 and breaking to ~$80. Hanwha's >$800M deal underwrites demand, but…

Generics-to-specialty re-rate keeps working CREXONT EU approval, romidepsin exclusivity and the $1.1B Kashiv biosimilar build carried the stock to a fresh 52-week high at $18.39, and UBS's 2026-07-15 move to $23 finally opens sell-side…

AI-interconnect picks-and-shovels narrative is price-confirmed: APH cleared the Jan $167.04 ATH with a $168.75 high (Jun 22) and drew a six-desk July 9–13 PT-raise cluster to $185–200. The July 29 Q2 print, and its book-to-bill, is the…

Advanced-packaging pricing power turned real quotes raised 20%+ (2026-07-01), 2026 capex hiked to US$8.5B, CoWoS-equivalent capacity tripling to 25k wpm but the tape topped at $45.51 the same day and sits ~15% lower at $38.82 inside a…

AI test-intensity arms dealer with the fundamental backdrop improving (TSMC 2026 capex hiked to $60–64B on 2026-07-16, ASML raised twice) while the tape sold the news ADR is ~18% off the 2026-06-25 record after a -6.9% July 16 session. The…

Turnaround compounding into acceleration: third FY2026 guidance raise (rev $2.63-2.65B, EBITDA $338-342M) on the June 1 close of the $175.5M Family First deal, with price +55% off $6.24 in six weeks to $9.69 against a $10.32 high.…

Post-LOTUS de-risked anti–IL-1β (abdakibart) story: the May 5 Phase 2 HS win (HiSCR75 ~42% vs 26% placebo) already re-rated the stock ~4x, and it is now fully funded into 2029, Russell-included, with sell-side initiating at $35–$38. But…

Q1 FY27 (2026-06-25) resolved the binary bullish: QNX royalties printed $72.3M vs the $60-64M guide, FY27 QNX guide raised to $295-312M, first cash-positive fiscal Q1 in nine years. The pivot narrative now has numbers behind it, not just a…

Argentina country trade re-accelerated: June CPI printed 1.9% MoM on 2026-07-14 (first sub-2% of the cycle) and country risk broke to 402bp, tightest since April 2018, carrying BBAR to a fresh 52-week high of $22.47. Price now sits above…

EMS arms-dealer to two secular ramps at once AI datacenter liquid-cooling (AC&C +41% YoY, Q1 CY2026) and the 2026-06-15 Ouster Rev8 lidar expansion (>100k units/yr, 10-yr life). Narrative accelerating, but the tape sits ~18% above the $78…

Structural de-risking is finally firing: board approved a Hong Kong dual-primary listing (2026-07-16, effective within 2026) removing the ADR-delisting tail, and Beijing's Apple Intelligence clearance (2026-07-15/16) puts Baidu inside…

Beaten-down B2B-fintech turnaround re-rating on self-help: Q3 delivered the first GAAP-profitable quarter, a $1.0B buyback, and a 30% headcount cut, driving a +40% leg off the June $32 low toward the 200-day at $49.42. A…

Neocloud storage pick-and-shovel confirmed: a five-year ~$335M CoreWeave B2 Neo contract (announced 2026-06-23) validated the white-label thesis and re-rated BLZE from the high-$7s to a fresh 52-week high near $18. Narrative accelerating,…

Dormant-to-leader flip held: the June base above $6 matured into a tight cup-and-handle at $7 while Webull stacked catalysts MCP AI-trading, Canada crypto, the $100M Pi Securities deal, and the 2026-07-07 Webull Institutional B2B launch.…

Cheap, high-margin insurtech SaaS put in play: a Morgan Stanley-run sale process plus a fresh Elliott activist stake. Shares popped ~13% to ~$6 on the 2026-07-09 Reuters report yet still sit below a plausible PE take-out. The trade is…

2nd-order AI-power name whose order book went vertical (Q1 orders +97%, b2b 2.2x); the closed Thermon merger doubled EBITDA and lifted recurring mix to ~40%. JPM initiated Overweight $130 on 2026-07-09 (street-high). Digesting a ~17%…

Edge-AI IP royalty narrative still accelerating: a 2026-07-06 custom-AI-silicon licensing deal and Stifel's 2026-07-10 raise to $50 stack three bulls above a ~$44 consensus as the stock presses its $51.25 52-wk high. Near $50, though, it…

Re-rated ~3x off the $5.68 low as the CD19 T-cell-engager-in-autoimmune narrative accelerated; CLN-978 remissions in lupus/RA (Immunology Day 2026-06-10) drove it. Now bull-flagging under the $19.43 high with no hard-dated catalyst until…

AI-networking EMS picks-and-shovels story still intact after the 2026-04-27 Q1 blowout (rev +53% to $4.05B, FY26 guide raised to $19B), but structure broke ~21% off the $474 June high and now coils into the binary 2026-07-27 Q2 print where…

BTC-miner-to-AI-infrastructure pivot is stalling: the Meta Sandersville lease is still unsigned ~5 weeks after the 2026-06-08 "in talks" report, June BTC output slipped to 614 (from 671), and shares slid into early July. A signed Meta…

Hormuz war-risk super-spike re-igniting: the US revoked Iran's sanctions waiver after 2026-07-06/07 Gulf ship attacks, VLCC Hormuz fixtures hit ~$470k/day (above the March peak) and the tanker ETF jumped ~20% on 2026-07-08. June's…

Interconnect/AEC royalty narrative still accelerating, not fading new 52-week highs on late-June initiations (Evercore $325, Stifel $350, BofA $340) plus the early-July AI-buildout rally. But it's now mainstream and widely held, entering a…

Turnaround re-rating picking up fresh fuel: Piper's 2026-06-26 upgrade to Overweight/$150 (3rd firm near $150) on North America DTC re-accelerating to mid-single-digit growth best since Q2 2024 plus a growing Himalaya Capital stake, pushes…

AI-infrastructure re-rate of a legacy networker, now digesting: after a +29% run to a $129.52 ATH (6/4) the stock has backfilled to the $118–120 breakout shelf near $121 the cleaner entry the vertical run never offered. The $9B FY26…

Utility T&D / grid-capex cycle with CTOS as the laggard specialty-rental picks-and-shovels name; the June breakout to $11.36 has stalled, retracing ~10% to retest the ~$10 shelf into a binary 2026-07-29 Q2 print. Theme now maturing and…

Single-banner turnaround re-rated on a Jul 6–8 sell-side upgrade cluster (JPM $170, UBS $145, Raymond James $140, Goldman off Sell to $125), pushing DLTR to $128.51 intraday Jul 15. Narrative is confirmed but no longer early, and the tape…

Single-asset complement biotech (claseprubart/DNTH103) broke out to a new 52-week high near $102 in July, reclaiming and extending well above the $81 March offering shelf as the Sanofi same-mechanism CIDP fear faded and analyst PTs…

Agentic-AI cloud re-rate re-accelerating: Q2 (2026-07-07) reported revenue growth jumping to 29% YoY from 14%, RPO >$800M, +20 MW capacity for 2027/28, plus Russell 1000 inclusion (2026-06-30). Citi/Barclays raised to ~$185; UBS lone bear…

Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT +…

Post-print collapse fully reversed: DSGN re-rated +40% in June to $15.19 (2026-07-10), reclaiming the $14.37 data-day high and pressing toward the $17.25 52-week high as the FA gene-therapy theme accelerated and the pipeline broadened…

GLP-1-fear-reversal + census-recovery re-rate is re-accelerating on clustered July analyst upgrades UBS to Buy/$270 (2026-07-10), Barclays $218 (2026-07-09) reopening headroom above the June ATH breakout; whale call flow (2026-07-03)…

Neuromuscular RNA-conjugate name re-rating near its 52-week high ($25) on a de-risked path: z-rostudirsen DMD exon-51 BLA submitted 2026-05-26 with Priority Review requested. The FDA filing/Priority-Review decision (~late July) and the…

Sell-side flipped from cutting to marking up in ten days five PT raises 2026-07-10→07-17 (JPM $94, Canaccord $97, Citi $92, RJ $87, UBS $80) on the e.l.f. Hair launch and Rhode scaling, while the stock slipped to $72.25. Narrative…

Post-EHA, de-risked best-in-class oral BCR::ABL1 asset (ELVN-001) heading to Phase 3 ENABLE-2 (2H 2026), over-funded at >$800M pro-forma after the $37.50 raise. The June 11 catalyst is spent, yet the sell-side is re-rating hard (PTs…

Probe-card pick-and-shovel to the HBM4 test ramp; after a parabolic run to a fresh $160.27 ATH (2026-06-30) on Russell 1000 inclusion, the 2026-07-02 chip selloff cut FORM ~24% to ~$121. HBM inflection intact (record DRAM quarter, second…

Software-supply-chain-security plus AI-agent "trust layer" narrative keeps re-rating: the analyst cluster now leads price above $100 (UBS Buy $110 Jul 2, Truist Buy $105 Jul 9), confirming the continuation tell flagged in June.…

Blood-based CRC screening narrative still accelerating: a second July cluster of PT raises pushed the Street high to $215 (Citi, 7/8), ~$40 — above June's $175 peak. GH is the theme leader re-rating higher, but the only fuel before the…

Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next…

Molecular-glue degrader story accelerating: Novartis-validated platform ($150M upfront, $2.1B milestones) plus a wholly-owned NLRP3/NEK7 asset (MRT-8102) that cut CRP 85% in Jan-2026 interim data. Guggenheim named GLUE an H2 top pick (PT…

Product-led monetization pivot re-accelerating: Q1 beat-and-raise (rev +38% to $130M, FY guide lifted to ≥$535M) plus Morgan Stanley's 2026-07-01 Overweight upgrade (PT $18) on the EDGE $100–500/mo ultra-premium tier and Woodwork…

Second-order AI/power play: Herc rents the cranes and gensets that build data centers. Peer United Rentals raised FY26 guidance (2026-04-23), confirming an accelerating theme but the stock sits +71% off its low and drifts into a binary…

Memory-capex WFE subsystem re-rating accelerating: Stifel and TD Cowen both to $115 (2026-07-09/10) after B. Riley's $125, dragging the old $71 Street target up toward the stock as Lam/Applied/Aehr peers break out together. Entry chases…

Legacy genomics monopoly in recognition-phase momentum on a clinical-sequencing inflection; sell-side just clustered at $200 (Guggenheim 06-29, Piper 07-01, Evercore 07-06) and 07-09 options whale alerts confirm positioning into the…

Memory-cycle re-rating in an AI costume just re-accelerated: June 2026 revenue +37.2% YoY and Q2 +28.7% YoY (both records since 2014, reported 2026-07-10) erase the May deceleration scare, and price bought back the ~17% fade to sit ~$68…

Post-sanctions PACE turnaround inflecting census +6.9% YoY, FY2026 adj-EBITDA guide raised to $85–90M, shares +51% off March lows (mostly P/S re-rate). The easy re-rate is largely done; now a mid-range consolidation with no catalyst for ~8…

Analyst-migration re-rate got a second leg with Morgan Stanley's 2026-07-13 upgrade to Overweight, PT $400 (implying spot ~$322–325), but news flow has gone silent since and the tape sits at ~28x forward with nothing scheduled until the…

Gas-compression operator repriced as a behind-the-meter data-center power supplier; the 2026-07-08 Baker Hughes multi-year turbine agreement de-risks the equipment supply chain for the >2 GW buildout, but the re-rating is sell-side-mature…

Turnaround re-rating went live in July: KMX broke the $50–$53 shelf to close $57.33 on 2026-07-17 (+17.2% in five sessions) after a Q1 FY27 blowout (EPS $1.31 vs ~$0.95, revenue $8.01B +6.2%), CEO Keith Barr buying 9,400 shares at $53.005…

Sell-side catch-up fired: Barclays (2026-07-14, $9→$13) and KeyBanc (2026-07-13, $11→$13) both raised to $13 within 24 hours, and LFST printed a fresh 52-week high at $11.68. Behavioral-health margin inflection is now consensus rather than…

Expedition-cruise turnaround: mid-$70s Brent and a record 2027 book drove +185% over the trailing year, and the street is now catching up Stifel to $32 (Jul 10), Benchmark to $34 (Jun 29), both above the ~$25.67 spot. The oil catalyst is…

Hormuz truce collapsed 2026-07-08 Iran re-struck shipping and re-closed the Strait, re-firing VLGC rates to fresh 2026 highs (BLPG3 $220/ton, TCE $125k/day, week of Jul 10). This pure-play VLGC name re-accelerated off its $36 late-June low…

YUTREPIA commercial ramp plus S&P SmallCap 600 inclusion and a SCOTUS-de-risked '327 overhang pushed LQDA to new highs near $80 — but the coiled asymmetry is spent: price now sits above the ~$69 consensus target with insiders selling into…

Thesis has flipped from cyclical rollover to agentic-distribution re-rate: P&C revenue +31.1% YoY in Q1 (2026-04-29), the autoinsurance.net ChatGPT app live since 2026-04-02, and price at a 52-week high of $14.39 (2026-07-15) some 38%…

APOL1 kidney precision-medicine story re-accelerating post-HORIZON: Phase 2 (Mar-25-2026) gave first broad-AMKD proof-of-concept (35.6% proteinuria cut, 61.8% in FSGS), stock reclaimed the April $23.50 raise, and a second oral asset…

Data-center power pivot is revenue-confirmed record >$80M FY26 segment sales and an FY27 guide ($1.025–1.075B vs ~$952M Street) but the post-print momentum leg has faded ~26% from the $20.38 high to ~$15. The re-rate is spent and the sell…

Platform inflection: Ryoncil delivered $115M first-year revenue above its $110-120M guide, and Mesoblast is stacking regulatory optionality a modular BLA filed for rexlemestrocel-L in LVAD heart failure plus a fully-enrolled Phase 3…

Agentic-ad-infra narrative kept adding legs post-Magnite Orchestration (2026-06-11) Viasat, then a Walmart Connect commerce-media deal carrying MGNI from ~$17.89 to the low-$20s. CTV is 51% of net revenue growing 30%, but clustered insider…

The $400M Oberland royalty deal (2026-07-07) took dilution and runway risk off the table and spiked MGTX to a new 52-week high of $15.35 before a fade to ~$12.44 a non-dilutive re-rate of a three-program AAV gene-therapy pipeline, but the…

AI-packaging/WFE picks-and-shovels re-rating: Q1 beat + FY guide raised to $4.79B, and the sell-side has now chased price with six PT hikes to $415–$600 (Jun 23–Jul 9), erasing the "above every analyst PT" cap. Theme ACCELERATING with…

Carve-out re-rate re-firing: MMED closed $16.93 on 2026-07-17 (+6.61%, volume 26% above average, intraday $17.15), reclaiming the $17 handle for the first time since the June fade on group confirmation from Abbott's 07-16 print and DXCM's…

AI/datacenter power-buildout supercycle lifting grid/electrical contractors; MYRG confirmed it with a record Q1 and a late-June breakout to fresh ATHs (~$487) above the $484.71 shelf. Theme ACCELERATING + cluster-confirmed, but the Q2…

NGN-401 Rett-syndrome gene-therapy narrative re-accelerated on the 2026-06-29 low-dose data update, strong enough to place a $125M raise at $30 the next day. Data and financing are now both out, so the next binary is FDA…

M&A read-through re-accelerating: AbbVie's $10.9B Apogee buyout (June 22, 2026) reframed NKTR as the next takeout-able Treg-IL-2 atopic-dermatitis asset, driving a ~25% run off the June low to ~$70. It's sympathy optionality, not fresh…

Bexobrutideg BTK-degrader franchise is re-rating: six firms raised targets to $32-40 on 2026-07-10, one day after a 44% Q2 revenue miss the sell-side dismissed as collaboration-revenue noise. EHA 2026 CLL durability is the driver, but the…

Falling knife has based and turned: after a -34% unwind from the $163 high to a ~$107 June base, a fresh cluster (Truist initiate Buy $140 07-14, Guggenheim upgrade Buy 07-15) plus a 07-15 surge is re-rating the M&A-drift story. The…

Digital-chronic-care re-rating accelerating: the GLP-1 wave expands rather than shrinks Omada's TAM as the scaled behavior-change layer on obesity drugs. Q1 beat-and-raise (rev +42% to $78M, FY guide lifted to $322–330M) plus a $30…

Supply overhang cleared: the 2026-07-01 Fairmount $300M block at $84.43 was absorbed and price closed $92.70 on 07-17 (+11.6%), 5% off the 52-week high, with 19.85% short interest still rising. Long-acting I&I re-rated by the $10.9B…

Setup inverted since the June breakdown. OXM reclaimed its 200-day ($39.11) and 50-day ($39.94) off the $35.83 low, the CEO bought 2,500 shares at $36.90 on 2026-06-12, and ~$25M of filed IEEPA tariff-refund claims 4% of market cap,…

Pharma copay-affordability leg compounding: Q1 (2026-05-12) patient-affordability revenue +82% YoY to $15.7M, pharma overtook plasma as largest segment. Price broke to a new 52-week high $9.30 and held $8.55 (2026-07-17), +89% in six…

The read has flipped from value trap to ownership story. Price reclaimed the 200-DMA (~$10.30 on 2026-07-17, +13% in three weeks), Truist lifted its PT to $11 on 2026-07-09, and the 2026-07-14 addition of Alex Shootman who sold Workfront…

Q3 (July 7) broke the model wide open: revenue $478.7M vs $405.5M consensus (+48% YoY), EPS $0.84 vs $0.54, FY26 growth guide lifted 12%→22% and FY27 pre-guided ~30%. The stock then round-tripped from $89.86 to ~$60 on the $750M…

iCasino-led digital turnaround gliding toward Q4-2026 interactive profitability while the regional-gaming cycle re-rates; sell-side is catching up in a cluster (Goldman Buy init $26, Susquehanna $28, both late-June/July). Alberta goes live…

Nuclear-cleanup inflection accelerating: Hanford vit-plant hot commissioning plus DOE grouting awards (200W ~$216M/yr, 200E ~$75M/yr) repricing a ~$62M-revenue cleanup contractor as a multi-bagger. Shares broke to a 52-week high (+13.6%…

PAPZIMEOS launch inflection accelerating the first and only FDA-approved RRP therapy printed $21.6M net product revenue in Q1 2026 (a beat), with cash-flow breakeven guided by year-end and orphan exclusivity to 2032; the ~Aug 10 Q2 print…

Fertility-benefits re-rate broke out rather than stalled: PGNY cleared the $28.75 shelf and printed a new 52-wk high $33.06, trading ~$31.9–32.5 after KeyBanc lifted its target to $35 on 7/13. Price now sits above the $30.73 consensus, so…

Diversified specialty-insurance compounder: GWP +42% to $629.8M in Q1 (2026-05-06), FY26 adjusted-income guide lifted to $262–278M at 20%+ ROE. But the stock has stalled ~8% under its $147.62 high, sell-side is splitting, and the…

Geopolitical crude bid re-fired after the 2026-07-08 US strikes and Hormuz blockade WTI back to ~$80 from $68.86, PNRG +8.9% MTD to $186.51 and above the 200-day. Structurally better than June: GCX in-service flipped Waha gas positive,…

Reciprocal-pivot re-rate has largely printed: $9.26 (6/5) to $15.98, now consolidating at $13.68 after KBW's 7/13 valuation downgrade that still raised its target to $16.25. Narrative intact but maturing; the 2026-08-04 Q2 print is the…

Monopoly wildfire retardant (PHOS-CHEK) into a season at national Preparedness Level 5 3.85M acres burned YTD (NIFC, 7/18), ~157% of the 10-yr average. JPM initiated Overweight $50 on 7/9, lifting the 4-analyst average target to $45. Price…

De-risked dual-royalty inflection: icotrokinra (oral IL-23, J&J) already FDA-approved and paying 6–10% royalties, rusfertide (PV, Takeda) with a 76.9% VERIFY Phase 3 heading into a Q3 2026 PDUFA. Stock tripled off $49 to an all-time high;…

First-ever-approval-for-microcystic-lymphatic-malformations narrative accelerating and de-risked: SELVA hit its endpoint (Feb 24, 2026), FDA granted rolling NDA review, first module filed June 29, 2026. But no binary inside 30 days NDA…

Narrative flipped from broken-fintech fade to live takeover situation: Stripe/Advent bid $60.50 (>$53B) on 2026-07-15 sent PYPL +17.2%, its best day ever, to $56.56. Board called it inadequate (Reuters 2026-07-17), meeting ~2026-07-20. ~7%…

Left-for-dead vuln-management de-rate has V-reversed on an AI narrative flip: AI-generated code and attackers now framed as an expanding vulnerability surface feeding demand back to the installed base. JPM upgraded Underweight→Neutral, PT…

Auto-insurance carrier ad-spend recovery is reaccelerating: QNST revenue growth snapped from +2% YoY (fiscal Q2) to +28% (Q3, $346.1M), and the Q4 guide implies ≥34% revenue / ≥67% EBITDA growth. Stock just broke to 52-week highs on ~3x…

RAPP broke to all-time highs at $42.62 (2026-07-17, +6.2%) on zero company news the move is pure sell-side re-rating (BTIG reiterated Buy/$65 on 7/16, consensus PT $56.64, 12 desks Strong Buy) with Phase 3 FOCUS now enrolling globally.…

Cross-border remittance profitability inflection is accelerating: Q1 2026 (May 6) net income +332% on revenue +25% and Adjusted EBITDA +74%, with FY guide raised. Clustered PT hikes to $30 (Goldman 06-29, Citizens 07-12) confirm sell-side…

Q2 deliveries beat and the full-year output forecast was RAISED (2026-07-15, ~5% rally), giving the July moving-average reclaim a fundamental leg. But the death cross from ~2026-05-27 is uncured and sell-side skew is still…

Post-binary re-rating extended by an analyst-coverage land grab: JP Morgan initiated Overweight $28 (2026-07-08) and Canaccord Buy $29 (2026-07-16) on top of the June upgrade wave, carrying RLAY to a new 52-week high of $20.19 (~450% TTM).…

Corrected cash math changes the read: the $50.0M Candid break fee received 2026-05-04 landed after the 3/31 balance sheet, so ~$97M gross cash sits against 5.30M shares (~$18.3/sh) versus a $16.42 quote. Buyer gets the cash distribution…

Merger arb that finally got a date. DOJ granted HSR early termination 2026-07-13 and both special meetings are set for 2026-08-14, removing the regulatory leg. RMAX $11.10 vs ~$11.86 blended (5.150 REAX at $2.21 plus the prorated $13.80…

The takeout fight re-fired: Forager returned 2026-06-29 with $5.25 cash 9% above the $4.80 the board killed in May and was rejected again 2026-07-13, the same day the board seated a Parthenon-affiliated director under a cooperation…

Deleveraging turnaround repricing: ~$96M / 116-unit refranchising cuts net debt ~$147M→~$51M, removing the going-concern tail that pinned RRGB near $2.46. Tape +38.7% since the ~2026-05-20 Q1 print, into the low-$7s near the $7.89 high.…

The pre-registered re-rate tell fired: Scotiabank flipped to Sector Outperform on 2026-07-06, lifting its target to $23.50 from $16 the second bank pivot after BofA. Price has run $15.91 (06-26) to $19.57 (07-17), reclaiming the ~$18…

Three-engine re-acceleration Shopee GMV +30%, Monee loan book +71%, Garena's best quarter in 5 years drove a Q1 beat (2026-05-12) and a +19% one-month recovery off the $77 low. Fundamentally accelerating, but the stock is short-term…

Next-gen DMD gene therapy filling the vacuum from Sarepta Elevidys's safety collapse; SGT-003 clean across 40 dosed (no DILI/TMA/myocarditis, May 4 2026 cutoff) with ~110% microdystrophin expression. +172% off the low to $10.42 the…

Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought is frontline AML label expansion (~10x TAM). Stock coils below 52-week-high resistance…

Data-center cooling fundamentals still accelerating (+70% DC guide, HVAC backlog $755.3M vs $451.3M) but price has round-tripped the entire June breakout $251.08 high to $211.73 on 2026-07-17, -10% in a month on macro and multiple…

Legacy open-web ad network repricing as a toll booth on AI answer surfaces: the 2026-06-16 DeeperDive ad-network launch (35% take rate, open to third-party LLMs/agents) plus the 2026-07-01 Wikitree win drove a breakout to 52-week highs…

Legacy vuln-scanner re-rated as an AI beneficiary: Hexa AI GA on Claude at a 60% tier premium, OpenAI Daybreak (2026-06-22), FedRAMP High/IL5 (2026-06-29), and four target raises in two weeks including Scotiabank's $26→$50 upgrade. Price…

Positive Phase 3 LEVEL topline in PH-HFpEF (early-June 2026) triggered a clustered analyst re-rate (Piper $50, Guggenheim $40, Cantor $35, Chardan initiates $27); oral levosimendan de-risked in an indication with no approved therapy. ESC…

Profitable anti-CD20 franchise (BRIUMVI) repricing on a credible MG second act; the June 9 Phase 1 print and the second FY2026 guidance raise (~$925M global) are now in the tape, so the low-$50s buy an extended, post-catalyst move above…

Cleanest listed AI-power IPP: 1,920-MW AWS nuclear PPA through 2042 (~$18B) plus record PJM capacity pricing ($329.17/MW-day cap) gives a contracted floor. But discovery is spent Goldman ($499) was last to initiate, Wells Fargo reaffirmed…

Activist breakup/sale special situation past its board-control catalyst: Starboard seated its 4th designee at the June 29 annual meeting and sale talk is intensifying, with the $700M TheFork-to-Amex cash sale proving the board will…

Second breakout leg confirmed: TRVI cleared the June $18.17 all-time high and printed $20.22 on a +9.85% July 17 session (8.3M shares, $19.07 close), lifting the tape ~+45% in six weeks on Phase 3 launch mechanics and institutional…

Legacy CPaaS repricing as agentic/voice-AI engagement infrastructure; the 2026-06-01 Cowen "turnaround complete" +20% gap held into July as KGI initiated Outperform $250 (07-02), but the momentum crowd is thinning Terranova sold (06-23) a…

Synthetic-DNA-as-AI-input narrative went vertical: the failed $70 breakout reclaimed and ran to a $105.47 high, +200%+ YTD with 85% of it since the 2026-05-21 analyst day. Targets now $102-$120 — but price sits above the $85.50 consensus…

Analog-cyclical recovery compounding into an AI-data-center-power re-rate; late-June PT-raise cluster (Stifel $360, UBS $350, Cantor $340) confirms the leg but lands after price, and the 2026-07-21 Q2 print is now the binary inside 30…

Vector AI ad-engine turnaround intact Strategic Grow +49% YoY Q1, guided +50-52% Q2, GAAP profit targeted Q4 2026. The $26-27 base held through June; a July 1 target hike (+6.7%) reclaimed ~$29-30, but Raymond James' June 29 Market Perform…

ZUSDURI launch ramp still accelerating Q1'26 revenue $51.0M (+152% YoY), ZUSDURI $29.2M (+109% QoQ), prescribers 102→256 and the stock has now broken out above the old $32.37 cap to a fresh 52-week high ($39.59). Spot sits above the…

New-management turnaround re-rating still accelerating: VAC punched through Goldman's $100 target to fresh 52-week highs (~$102–106), and Deutsche Bank's June 30 hike to $119 (Buy) reset the ceiling above the tape. But it's extended near…

Sell-side is now chasing a move it missed: VCYT broke to a 52-wk high $60.91 (closed $59.13 on 2026-07-17, +124% YoY) as Piper initiated Overweight $66 (07-15) and Canaccord lifted a Hold PT $42→$60. Fundamentals still accelerating (Q1 rev…

Aircraft engine-leasing supercycle spare-engine shortage plus MRO backlog holding lease rates >20% above 2019 drove WLFC's record Q1 (rev +23% to $194.3M, EPS $4.03 vs $3.02 est). Fundamentals still accelerating but the theme is maturing…

Domestic trailer OEM re-rating on a policy moat: preliminary 82–129% countervailing + 131% antidumping duties on Chinese van trailers (June 2026) plus a DA Davidson upgrade (PT $8.50→$20) roughly doubled the stock off its low. The ~Aug-24…

Produced-water midstream re-rate is now being underwritten rather than discovered: shares hit a 52-week high $20.48 (2026-07-17 close $20.33, +73.6% YTD) as consensus PT walked from ~$17.30 to ~$21.83 and Russell Growth-Defensive inclusion…

Palantir Foundry re-platforming now has a management clock phase one guided complete within 30–40 days of the 2026-07-06 Citi event, landing on the ~2026-08-04 Q2 print. Price reclaimed the $21 shelf that capped the June recovery (+14%…

MIPLYFFA's patent cliff was pushed to 2041 (Orange Book listing 2026-06-08), and three weeks on the re-rating has held ZVRA sits ~$13.80, near its $14.58 52-week high, rather than fading. But the discrete catalyst is behind the tape; the…